Takeda Pharmaceutical said on February 10 that it has filed darvadstrocel (development code: Cx601) in Japan for the treatment of complex perianal fistulas associated with Crohn’s disease (CD) - the company’s first allogeneic stem cell therapy in the country. The…
To read the full story
Related Article
- MHLW Panel Backs Takeda’s Cell Therapy Darvadstrocel for Complex Anal Fistulas in CD
September 7, 2021
- Takeda’s 1st Cell Therapy Up for PAFSC Review on Sept. 6
August 24, 2021
BUSINESS
- Shionogi, Susmed End Sales Partnership for Insomnia App
August 27, 2026
- Nxera to Earn US$10 Million Milestone as Alzheimer’s Candidate Moves to PII
August 27, 2026
- Takeda’s XFG-Targeted COVID Jab Approved in Japan
August 27, 2026
- Meiji Wins Japan Approval for NB.1.8.1-Adapted COVID Vaccine
August 27, 2026
- Japan Pharma Market Seen Topping 11 Trillion Yen by 2035: Fuji Keizai
August 26, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





